logo
  

Stock Alert: Gilead Down 4% On Remdesivir Trial Data

Shares of Gilead Sciences (GILD) are slipping nearly 4% on Monday morning hurt largely by the latest data from its trials of remdesivir in patients with COVID-19.

Gilead said that in its late-stage clinical trials of patients in 5-day remdesivir treatment were 65% more likely to show clinical improvement, compared with those receiving standard care.

However, no statistically significant improvement showed in patients taking a 10-day course of the medicine.

"Our understanding of the spectrum of SARS-CoV-2 infection severity and presentations of COVID-19 continues to evolve," said Francisco Marty, MD, an infectious diseases physician at Brigham and Women's Hospital, and associate professor of medicine at Harvard Medical School. "These study results offer additional encouraging data for remdesivir, showing that if we can intervene earlier in the disease process with a 5-day treatment course, we can significantly improve clinical outcomes for these patients."

Remdesivir is currently approved in Japan as a treatment for patients infected with SARS-CoV-2, the virus that causes COVID-19. Outside of Japan, remdesivir is an investigational, unapproved drug.

The U.S. Food and Drug Administration granted remdesivir an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19; the authorization is temporary and does not take the place of the formal new drug application submission, review and approval process.

GILD is currently trading at $74.74, down $3.09 or 3.97%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning. Science and technology firm Danaher Corp. (DHR) announced Thursday that it has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance... Biopharmaceutical company Kite Pharma, a part of Gilead Sciences, Inc. (GILD), and biotechnology company Shoreline Biosciences, Inc. announced Thursday a strategic partnership to develop novel cell therapies across a variety of cancer targets. The partnership follows Kite's investment in Shoreline's...
Follow RTT